180 related articles for article (PubMed ID: 36635455)
21. Improving the prediction of persistent and recurrent differentiated thyroid cancer using the American Thyroid Association 2015 risk stratification system.
Markantes GK; Karakioulaki M; Papanikolopoulou S; Theodoropoulou A; Markou KB; Vagenakis AG; Spyridonidis T; Goulis DG; Michalaki MA
Hormones (Athens); 2021 Dec; 20(4):761-768. PubMed ID: 34383288
[TBL] [Abstract][Full Text] [Related]
22. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes.
Mihailovic J; Nikoletic K; Srbovan D
J Nucl Med; 2014 May; 55(5):710-7. PubMed ID: 24722527
[TBL] [Abstract][Full Text] [Related]
23. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
24. Intermediate-risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long-term outcome study.
Ballal S; Soundararajan R; Garg A; Chopra S; Bal C
Clin Endocrinol (Oxf); 2016 Mar; 84(3):408-16. PubMed ID: 25823589
[TBL] [Abstract][Full Text] [Related]
25. Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine.
Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
Endocrine; 2023 Apr; 80(1):79-85. PubMed ID: 36367673
[TBL] [Abstract][Full Text] [Related]
26. PSMA Expression in Differentiated Thyroid Cancer: Association With Radioiodine, 18FDG Uptake, and Patient Outcome.
Ciappuccini R; Saguet-Rysanek V; Giffard F; Licaj I; Dorbeau M; Clarisse B; Poulain L; Bardet S
J Clin Endocrinol Metab; 2021 Nov; 106(12):3536-3545. PubMed ID: 34331544
[TBL] [Abstract][Full Text] [Related]
27. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
28. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
29. A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes.
Wijewardene A; Gill AJ; Gild M; Learoyd DL; Glover AR; Sywak M; Sidhu S; Roach P; Schembri G; Hoang J; Robinson B; Tacon L; Clifton-Bligh R
Thyroid; 2022 Oct; 32(10):1201-1210. PubMed ID: 35620896
[No Abstract] [Full Text] [Related]
30. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
Wu J; Hu XY; Ghaznavi S; Kinnear S; Symonds CJ; Grundy P; Parkins VM; Sharma P; Lamb D; Khalil M; Hyrcza M; Chandarana SP; Pasieka JL; Harvey A; Warshawski J; Hart R; Deutschman M; Randall DR; Paschke R
Thyroid; 2022 Dec; 32(12):1509-1518. PubMed ID: 36226405
[No Abstract] [Full Text] [Related]
31. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
32. Second Adjuvant Radioiodine Therapy after Reoperation for Locoregionally Persistent or Recurrent Papillary Thyroid Carcinoma.
Cadena-Piñeros E; Escobar JV; Carreño JA; Rojas JG
World J Nucl Med; 2022 Dec; 21(4):290-295. PubMed ID: 36398303
[No Abstract] [Full Text] [Related]
33. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.
Schvartz C; Bonnetain F; Dabakuyo S; Gauthier M; Cueff A; Fieffé S; Pochart JM; Cochet I; Crevisy E; Dalac A; Papathanassiou D; Toubeau M
J Clin Endocrinol Metab; 2012 May; 97(5):1526-35. PubMed ID: 22344193
[TBL] [Abstract][Full Text] [Related]
34. Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment.
Yi W; Kim BH; Kim M; Ryang SR; Jang MH; Kim JM; Kim EH; Jeon YK; Kim SS; Kim IJ
Endocr J; 2020 Dec; 67(12):1193-1198. PubMed ID: 32727965
[TBL] [Abstract][Full Text] [Related]
35. Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer.
Wang TS; Evans DB; Fareau GG; Carroll T; Yen TW
Ann Surg Oncol; 2012 Dec; 19(13):4217-22. PubMed ID: 23010732
[TBL] [Abstract][Full Text] [Related]
36. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.
Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB
Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of radioiodine therapy for treating 20 patients with pulmonary metastases from differentiated thyroid cancer and a meta-analysis of the current literature.
Zhang X; Liu DS; Luan ZS; Zhang F; Liu XH; Zhou W; Zhong SF; Lai H
Clin Transl Oncol; 2018 Jul; 20(7):928-935. PubMed ID: 29119458
[TBL] [Abstract][Full Text] [Related]
38. Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine.
Momesso DP; Vaisman F; Yang SP; Bulzico DA; Corbo R; Vaisman M; Tuttle RM
J Clin Endocrinol Metab; 2016 Jul; 101(7):2692-700. PubMed ID: 27023446
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
[TBL] [Abstract][Full Text] [Related]
40. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients.
Castagna MG; Cevenini G; Theodoropoulou A; Maino F; Memmo S; Claudia C; Belardini V; Brianzoni E; Pacini F
Eur J Endocrinol; 2013 Jul; 169(1):23-9. PubMed ID: 23594687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
